Company Overview

OraSure Technologies is a leader in the development, manufacture and distribution of oral fluid diagnostic and collection devices and other technologies designed to detect or diagnose critical medical conditions. Its innovative products include rapid tests for the detection of antibodies to HIV and HCV at the point of care and testing solutions for detecting various drugs of abuse. In addition, through its wholly-owned subsidiary, DNA Genotek Inc., the Company also is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. OraSure's portfolio of products is sold globally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, research and academic institutions, distributors, government agencies, physicians' offices, and commercial and industrial entities. The Company's products enable healthcare providers to deliver critical information to patients, empowering them to make decisions to improve and protect their health.   For more information on OraSure Technologies, please visit www.orasure.com.
 
DNA Genotek
Based in Ottawa, Canada, DNA Genotek focuses on providing high-quality biological sample collection, stabilization and preparation products. The company's lead product, the Oragene®•DNA Self-Collection Kit, is the easiest way to collect and preserve large amounts of DNA from saliva.

Executive Team

• Douglas A. Michels, President and Chief Executive Officer
• Ronald H. Spair, Chief Operating Officer and Chief Financial Officer
• Stephen R. Lee, Executive Vice President and Chief Science Officer
• P. Michael Formica, Executive Vice President and General Manager, Cryosurgery
• Anthony Zezzo, Executive Vice President, Marketing and Sales
• Henry B. Cohen, Senior Vice President, Human Resources
• Ian Curry, President, DNA Genotek, Inc.
• Robert Gregg, Senior Vice President, Regulatory Affairs
• Debra Y. Fraser-Howze, Senior Vice President, Government and External Affairs
• Jack E. Jerrett, Senior Vice President, General Counsel and Secretary
• Nancy McLane, Senior Vice President, Operations
• Ron Ticho, Senior Vice President, Corporate Communications

Clients

OraSure Technologies' client base includes hospitals, public health agencies, physicians' offices, clinical laboratories, workplace sites, insurance companies and criminal justice facilities in the United States and abroad.

Employees

330

OraSure Technologies develops, manufactures and markets point-of-care, oral fluid specimen collection devices that leverage proprietary oral fluid technologies, diagnostic products, including immunoassays and other in vitro diagnostic tests, and other medical devices.

OraSure Technologies’ current products are as follows:

HIV

• OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test – the first and only FDA approved, CLIA-waived, rapid point-of-care test that can detect antibodies to both HIV-1 and HIV-2 with greater than 99% accuracy in as little as 20 minutes, using an oral fluid, finger-stick or venipuncture whole blood, or plasma sample.
• OraSure® HIV-1 Oral Fluid Specimen Collection Device – the only FDA-approved, laboratory-based collection device that collects oral fluid to test for antibodies to the HIV-1 virus.

HCV

• OraQuick® HCV Rapid Antibody Test – the first and only FDA-approved rapid HCV test in the U.S. OraQuick® HCV is approved for the detection of HCV antibodies in venous whole blood specimens for individuals at risk. The test received the CE Mark for use with oral fluid, whole blood, serum and plasma for HCV.

Influenza

• OraSure QuickFlu(TM) Rapid Flu A+B Test – an FDA-cleared, in vitro rapid qualitative test for the detection of influenza (flu) type A and type B, including H1N1 viral infections. The test specimen is collected with a nasal swab, nasopharyngeal swab, or nasal aspirate/wash and results are available in as little as 10 minutes.

Substance Abuse

• Intercept® Oral Fluid Drug Testing System – Intercept® is an FDA-cleared oral fluid drugs of abuse test that provides a smart alternative to costly, inconvenient and often embarrassing urine drug testing. This testing service detects the "NIDA-5" drug panel (marijuana, cocaine, opiates, PCP and amphetamines) plus barbiturates, methadone and benzodiazepines without the need to collect urine.
• Q.E.D® Saliva Alcohol Test – an FDA-cleared on-site, low-cost alternative to breath or blood testing for alcohol. The test is easy to administer and provides quantitative results as accurate as a blood test.

Portable Cryosurgery

• Histofreezer® Portable Cryosurgical System – an FDA-cleared, low-cost, highly effective cryosurgical system for medical professional use for the treatment of common warts and benign skin lesions.
• Scholl Freeze – cryosurgical wart treatment product sold over-the-counter in Europe for the treatment of common and plantar warts; manufactured by OraSure and distributed by Rickitt Benckiser plc.
• Pointts® Wart Remover – cryosurgical wart treatment product sold over-the-counter in Central and Latin America for the treatment of common and plantar warts; manufactured by OraSure and distributed by Genomma Lab

In addition, through its wholly-owned subsidiary, DNA Genotek Inc., the Company also is a leading provider of oral fluid sample collection, stabilization and preparation products for molecular diagnostic applications. The company's lead product, the Oragene®•DNA Self-Collection Kit, is the easiest way to collect and preserve large amounts of DNA from saliva

Selected Financial Information